Students surging toward medical schools: ‘If there’s another pandemic, it’ll be up to us’

Somewhat suddenly, Boston University’s school of medicine has in hand 12,024 applications from students hoping to become MDs. It only has 110 seats. Across the country, Stanford has 11,000 applicants for 90 openings.

Too many applicants is a good problem to have, especially in a time of looming physician shortages, and in 2020 it has a name: the “Fauci effect.”

“[P]eople people look at Anthony Fauci, look at the doctors in their community and say, ‘You know, that is amazing. This is a way for me to make a difference,’” Kristen Goodell, MD, associate dean of medical-student admissions at BU, tells NPR.

Asked about the naming of the effect, Fauci says it’s “very flattering.”

However, he suggests, a more realistic scenario is that the surge is “the effect of a physician who is trying to and hopefully succeeding in having an important impact on an individual’s health, as well as on global health. So if it works to get more young individuals into medical school, go ahead and use my name. Be my guest.”

That would be good, as the U.S. has been heading toward a deficit of as many as 139,000 physicians by 2033, according to the Association of American Medical Colleges.

“Everyone feels some sort of responsibility,” Mary Grace Kelley, a medical assistant who has decided to restart her stalled pursuit of an MD, tells NPR. “There’s definitely a call to arms thinking that, if there’s another pandemic, it’ll be up to us.”

Read the whole thing.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.